MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598846 | Name: Lifarizine methanesulfonate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lifarizine methanesulfonate is a sodium-calcium channel modulator that reduces ischemic brain damage.

Chemical Structure

Lifarizine methanesulfonate
Lifarizine methanesulfonate
CAS#130565-83-2

Theoretical Analysis

MedKoo Cat#: 598846

Name: Lifarizine methanesulfonate

CAS#: 130565-83-2

Chemical Formula: C30H36N4O3S

Exact Mass: 532.2508

Molecular Weight: 532.70

Elemental Analysis: C, 67.64; H, 6.81; N, 10.52; O, 9.01; S, 6.02

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Lifarizine methanesulfonate;
IUPAC/Chemical Name
1-benzhydryl-4-((5-methyl-2-(p-tolyl)-1H-imidazol-4-yl)methyl)piperazine methanesulfonate
InChi Key
CGPIUYHUELMXMK-UHFFFAOYSA-N
InChi Code
InChI=1S/C29H32N4.CH4O3S/c1-22-13-15-26(16-14-22)29-30-23(2)27(31-29)21-32-17-19-33(20-18-32)28(24-9-5-3-6-10-24)25-11-7-4-8-12-25;1-5(2,3)4/h3-16,28H,17-21H2,1-2H3,(H,30,31);1H3,(H,2,3,4)
SMILES Code
CC1=C(CN2CCN(C(C3=CC=CC=C3)C4=CC=CC=C4)CC2)N=C(C5=CC=C(C)C=C5)N1.CS(=O)(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 532.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Brown NA, Kemp JA, Seabrook GR. Block of human voltage-sensitive Na+ currents in differentiated SH-SY5Y cells by lifarizine. Br J Pharmacol. 1994 Oct;113(2):600-6. PubMed PMID: 7834213; PubMed Central PMCID: PMC1510106. 2: Budd DC, May GR, Nicholls DG, McCormack JG. Inhibition by lifarizine of intracellular Ca2+ rises and glutamate exocytosis in depolarized rat cerebrocortical synaptosomes and cultured neurones. Br J Pharmacol. 1996 May;118(1):162-6. PubMed PMID: 8733590; PubMed Central PMCID: PMC1909495. 3: MacKinnon AC, Wyatt KM, McGivern JG, Sheridan RD, Brown CM. [3H]-lifarizine, a high affinity probe for inactivated sodium channels. Br J Pharmacol. 1995 Jul;115(6):1103-9. PubMed PMID: 7582509; PubMed Central PMCID: PMC1908993. 4: McBean DE, Winters V, Wilson AD, Oswald CB, Alps BJ, Armstrong JM. Neuroprotective efficacy of lifarizine (RS-87476) in a simplified rat survival model of 2 vessel occlusion. Br J Pharmacol. 1995 Dec;116(8):3093-8. PubMed PMID: 8719782; PubMed Central PMCID: PMC1909165. 5: May GR, Rowand WS, McCormack JG, Sheridan RD. Neuroprotective profile of lifarizine (RS-87476) in rat cerebrocortical neurones in culture. Br J Pharmacol. 1995 Apr;114(7):1365-70. PubMed PMID: 7606340; PubMed Central PMCID: PMC1510289. 6: McGivern JG, Patmore L, Sheridan RD. Actions of the novel neuroprotective agent, lifarizine (RS-87476), on voltage-dependent sodium currents in the neuroblastoma cell line, N1E-115. Br J Pharmacol. 1995 Apr;114(8):1738-44. PubMed PMID: 7599943; PubMed Central PMCID: PMC1510400. 7: Alps BJ, Calder C, Wilson AD, McBean DE, Armstrong JM. Reduction by lifarizine of the neuronal damage induced by cerebral ischaemia in rodents. Br J Pharmacol. 1995 Aug;115(8):1439-46. PubMed PMID: 8564203; PubMed Central PMCID: PMC1908890. 8: Brown CM, Calder C, Linton C, Small C, Kenny BA, Spedding M, Patmore L. Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia. Br J Pharmacol. 1995 Aug;115(8):1425-32. PubMed PMID: 8564201; PubMed Central PMCID: PMC1908884. 9: Sheridan RD. Selectivity of the neuroprotective agent lifarizine. Trends Pharmacol Sci. 1995 Sep;16(9):292. PubMed PMID: 7482992. 10: Brown CM, Calder C, Alps BJ, Spedding M. The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil. Br J Pharmacol. 1993 May;109(1):175-7. PubMed PMID: 8388296; PubMed Central PMCID: PMC2175597. 11: Mestre M, Djellas Y, Carriot T, Cavero I. Frequency-independent blockade of cardiac Na+ channels by riluzole: comparison with established anticonvulsants and class I anti-arrhythmics. Fundam Clin Pharmacol. 2000 Mar-Apr;14(2):107-17. PubMed PMID: 10796057. 12: Squire IB, Lees KR, Pryse-Phillips W, Kertesz A, Bamford J. Efficacy and tolerability of lifarizine in acute ischemic stroke. A pilot study. Lifarizine Study Group. Ann N Y Acad Sci. 1995 Sep 15;765:317-8. PubMed PMID: 7486628. 13: Cramer WC, Toorop GP. Focal cerebral ischemia in the mouse: hypothermia and rapid screening of drugs. Gen Pharmacol. 1998 Feb;30(2):195-200. PubMed PMID: 9502174. 14: Rataud J, Debarnot F, Mary V, Pratt J, Stutzmann JM. Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci Lett. 1994 May 19;172(1-2):19-23. PubMed PMID: 8084530. 15: Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology. 1997 Nov;49(5 Suppl 4):S66-9. Review. PubMed PMID: 9371155. 16: Spedding M. Reasons why stroke trials underestimate the neuroprotective effects of drugs. Stroke. 2002 Jan;33(1):324-5. PubMed PMID: 11779937. 17: Deffois A, Fage D, Carter C. Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain. Neurosci Lett. 1996 Dec 13;220(2):117-20. PubMed PMID: 8981487. 18: Alps BJ. Drugs acting on calcium channels: potential treatment for ischaemic stroke. Br J Clin Pharmacol. 1992 Sep;34(3):199-206. Review. PubMed PMID: 1327050; PubMed Central PMCID: PMC1381389. 19: Kucharczyk J, Mintorovitch J, Moseley ME, Asgari HS, Sevick RJ, Derugin N, Norman D. Ischemic brain damage: reduction by sodium-calcium ion channel modulator RS-87476. Radiology. 1991 Apr;179(1):221-7. PubMed PMID: 2006281. 20: Kucharczyk J, Mintorovich J, Sevick R, Asgari H, Moseley M. MR evaluation of calcium entry blockers with putative cerebroprotective effects in acute cerebral ischaemia. Acta Neurochir Suppl (Wien). 1990;51:254-5. PubMed PMID: 2089909.